Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
about
Immune Checkpoint Inhibitors in Melanoma and HIV Infection.Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models.Liquid biomarkers in melanoma: detection and discovery.Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.The Role of the Estrogen Pathway in the Tumor Microenvironment.Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy.Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management.Cutaneous melanoma: From pathogenesis to therapy (Review).Clinical Development of PD-1 in Advanced Melanoma.Current PD-L1 immunohistochemistry for non-small cell lung cancer.Mechanisms and Therapy for Cancer Metastasis to the Brain.Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer.Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy.Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab.Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma.Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection.PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancerDendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time2018 Nobel Prize in physiology or medicineEfficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysisPD-1 deficiency is not sufficient to induce myeloid mobilization to the brain or alter the inflammatory profile during chronic neurodegeneration
P2860
Q47138765-14E98D23-9688-4081-BC48-4285B7F0CB7BQ47301132-E250CDB9-630C-4399-8F14-6CEEE9F16BA9Q47304240-75CF186A-6865-4F40-A8B1-35919E3139FDQ47375181-1F249667-40D9-4CB3-AD42-017D57663ACDQ47602416-9A1643F6-1D3D-4D39-AB91-42E222E11C46Q47726847-B40892A1-B4EF-408F-90B6-FF90FB093DBFQ48517891-BC1B7E77-F8F8-4D04-AD0E-F11C3829CA6AQ49803828-459B1F92-EC08-457E-B600-7108E5E242D1Q52582136-CBD935B1-8BF9-4588-8F0F-5B0E2589FC1AQ52611551-9FD42DFD-C975-4BCC-A615-96AD37BEDA72Q52658584-F4EE7E0D-D0CE-4E5C-B64A-F26A5AC65144Q52707889-FD148720-9A27-4215-8908-28AE434B74E7Q52803955-8B8E2CD7-2EC0-4858-8E6C-0440A78C41E2Q54950354-0AC6AB05-8C1A-4ECF-831E-868E73E4B19FQ55098219-5264B291-A6B1-42F2-B8FF-809D07C03466Q55250324-C12FAFC3-F302-413E-A1D3-A312F3ADD58BQ55321107-5AAEA23F-D4E7-4453-8C24-CE6AE613EC10Q55342245-36A4E4A7-5BE0-4B40-9F3F-0BB339999F28Q55358698-D9994C03-4168-4E1F-9DF0-210E16C18B2DQ55418935-441A6EF6-BF5F-468B-8884-8DDD0CF661ADQ57073426-1F3F0A8A-7693-4E21-BED4-5B7554BCE579Q57486475-9D3784AB-E825-4451-BA3B-B88E4F827ACEQ58565746-4B88CBC0-ADEA-4DF3-953B-872E650B683DQ58756789-6006FFBE-7454-4728-90DB-38CC04FEB875Q58791590-36882C1B-0094-4A0B-B8BC-B52324E784CB
P2860
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Pembrolizumab versus ipilimuma ...... l phase 3 study (KEYNOTE-006).
@en
type
label
Pembrolizumab versus ipilimuma ...... l phase 3 study (KEYNOTE-006).
@en
prefLabel
Pembrolizumab versus ipilimuma ...... l phase 3 study (KEYNOTE-006).
@en
P2093
P50
P1433
P1476
Pembrolizumab versus ipilimuma ...... l phase 3 study (KEYNOTE-006).
@en
P2093
Antoni Ribas
Bart Neyns
Catriona McNeil
Christian Blank
Honghong Zhou
Jacob Schachter
James Larkin
Jean-Jacques Grob
Matteo S Carlino
Michal Lotem
P356
10.1016/S0140-6736(17)31601-X
P407
P577
2017-08-16T00:00:00Z